Zenas BioPharma, Inc. (ZBIO) Stock
ZBIO has an Alpha Score of 31 out of 100 (poor), computed on Nov 8, 2026 from 2 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported ZBIO in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $16.76M.
What is ZBIO's Alpha Score?
How it works →Alpha Score of 31 reflects weak overall profile with moderate momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 8, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own ZBIO?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 660K | $16.76M | +39% |
| Marshall Wace | 323K | $8.21M | -36% |
| Citadel Ken Griffin | 196K | $4.97M | +193% |
| Point72 Steve Cohen | 16K | $409.5K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are ZBIO's key statistics?
Key statistics as of Oct 31, 2026
ZBIO price chart
Powered by TradingViewWhat does Zenas BioPharma, Inc. do?
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company focuses on advancing innovative immunology-based treatments, with a strong commitment to addressing diseases characterized by significant unmet medical needs. Zenas BioPharma's pipeline features lead candidates such as obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, and orelabrutinib, a highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in Phase 3 development for multiple sclerosis and other autoimmune indications. The firm's portfolio also includes other monoclonal antibodies and immunomodulators under investigation for disorders like immunoglobulin G4-related disease and systemic lupus erythematosus. Guided by values emphasizing innovation, urgency, and patient impact, Zenas BioPharma operates with the aim of bringing novel treatment options to patients, their families, and caregivers, ultimately seeking to improve quality of life and redefine therapeutic possibilities in the autoimmune sector.